The second phase of behavioral testing involved assessing for the long-lasting consequences of chronic CNO-mediated hM3Dq DREADD activation of CamKIIα-positive forebrain excitatory neurons in adulthood, with behavioral tests for anxiety- and despair-like behavior commencing 3 months post cessation of CNO treatment (Figure 3K; Figure 3—figure supplement 1F). The gene discussed is CAMK2A; the disease is Anxiety.